- Filament Health (NEO: FH) has received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances
- The phase 1 trial will include 20 healthy subjects and examine the effects of Filament’s three proprietary botanical drug candidates
- Filament Health CEO Benjamin Lightburn sat down with Caroline Egan to discuss the clinical trial
- Filament Health (FH) is an exclusively-natural psychedelic drug discovery and extraction technology company
- Filament Health Corp. (FH) opened trading at C$0.315 on the NEO Exchange
Filament Health (NEO: FH) has received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances.
In addition, this approval is the first for the direct administration of psilocin rather than its prodrug psilocybin.
The phase 1 trial is led by the Translational Psychedelic Research Program (TrPR) at the University of California San Francisco.
Filament Health CEO Benjamin Lightburn sat down with Caroline Egan to discuss the clinical trial.
“We are excited to announce this milestone as validation of our ability to cultivate variable psychedelic biomass and transform it into pharmaceutical-grade drug candidates.
Our innovative technology has allowed us to create IP-protected botanical drug candidates of oral psilocin, sublingual psilocin, and oral psilocybin, and to enter them into an FDA-approved natural psychedelic clinical trial.”
The phase 1 trial will include 20 healthy subjects and examine the effects of Filament’s three proprietary botanical drug candidates: PEX010 (oral psilocybin), PEX020 (oral psilocin), and PEX030 (sublingual psilocin). To date, synthetic manufacturers have been unable to produce a stable formulation of psilocin and enter it into a clinical trial.
Filament Health (FH) is an exclusively-natural psychedelic drug discovery and extraction technology company.
Filament Health Corp. (FH) opened trading at C$0.315 on the NEO Exchange.
